Appropriate selection of patients for 1st line monotherapy in advanced or unresectable HCC and treatment management in relation with AEs
Appropriate selection of patients for 1st line monotherapy in advanced or unresectable HCC and treatment management in relation with AEs
Prof Richard Finn, Dr. Mohamed Bouattour, Prof. James Harding, Dr. Su Pin Choo
This HCC CONNECT e-learning programme helps to provide an understanding of the management of patients with advanced or unresectable HCC and who could benefit from VEGFR-TKI monotherapy in first-line setting
E-learning |
83 min
|accreditation:
EACCME |
Feb 2022
I agree that this educational programme:
The international faculty for this HCC CONNECT virtual Experts Knowledge address “Appropriate selection of patients for first-line monotherapy in advanced or unresectable HCC and treatment management in relation with AEs”. The faculty explore the profile of patients with advanced or unresectable HCC who could benefit from VEGFR-TKI monotherapy in first-line setting, explore real-world evidence, discuss the safety profile of the monotherapies, look into the future, with the potential promising combination therapies in the treatment of HCC and also provides an update on key HCC data presented recently at ASCO GI 2022.
This accredited e-learning will provide you with an overview of selection of patients for 1st line monotherapy in HCC
- The patient-profile who could benefit from VEGFR-TKI monotherapy 1st line in advanced or unresectable HCC
- Real-world data with monotherapy and the implications for clinical practice
- The safety profile of the monotherapies, be able to recognise the cause of toxicities and know the appropriate dosing strategies to manage side effects
- A look into the future, the potential of combination therapies in the treatment of HCC
Meeting Video Chapters
00:00 Faculty and Disclaimer
00:15 Who Can Benefit from VEGFR-TKI Monotherapy Today? Prof Finn
18:38 What did we learn from the real-world data? What can we translate into clinical practice? Dr Bouattour
36:44 Treating patients with VEGFR-TKI monotherapy:
What are the treatment related AEs and how to manage them? Prof Harding
56:06 Latest updates in HCC from ASCO GI 2022 (HIMALAYA study, KEYNOTE-394 trial, LAUNCH study). Dr Choo
1:18:42 A look to future treatments. Prof Finn
HCC CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer, AstraZeneca and from Eisai Europe Limited.
Other programmes of interest
Other programmes developed by Dr. Mohamed Bouattour
Dr. Mohamed Bouattour
Hepatologist and Gastroenterologist
Beaujon University Hospital
France
Other programmes developed by Prof. James Harding
Prof. James Harding
Medical Oncologist
Memorial Sloan Kettering Cancer Center
United States (US)
Other programmes developed by Dr. Su Pin Choo
Dr. Su Pin Choo
Medical Oncologist
Curie Oncology
Singapore